[Transdermal estrogenic therapy in menopause].
The availability of percutaneous estrogenic preparations capable of directly entering the bloodstream, avoiding the liver, has opened new prospects in the treatment of the climacteric syndrome. The purpose of our work has been to compare the effectiveness and tolerability of a percutaneous 17-beta-estradiol-oral progestin association with an all oral association of conjugated estrogens and progestins and to evaluate the ability to control menopausal symptoms and biohumoral characteristics. 42 (1 to 7 years postmenopausal) heavily symptomatic patients were selected at the "Centro per lo studio e la terapia del climaterio" in Milan and divided in two equally sized groups. One group was treated using the percutaneous therapy, the other with the all-oral one. The results show that percutaneous administration leads to a quicker control of vasomotor symptomatology and metabolic effects similar to oral administration.
Nencioni
T
T
Polvani
F
F
Penotti
M
M
Porcaro
E
E
Barbieri Carones
M
M
D000279:Administration, Cutaneous; D000284:Administration, Oral; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D004361:Drug Tolerance; D004958:Estradiol / Q000008:administration & dosage*; D004966:Estrogens, Conjugated (USP) / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008525:Medroxyprogesterone / Q000008:administration & dosage / Q000031:analogs & derivatives; D017258:Medroxyprogesterone Acetate; D008593:Menopause / Q000187:drug effects*; D008875:Middle Aged; D013997:Time Factors
D004966:Estrogens, Conjugated (USP); D004958:Estradiol; D017258:Medroxyprogesterone Acetate; D008525:Medroxyprogesterone
Terapia estrogenica per via transdermica in menopausa.